Hypertensive Crises in Critical Care: Insights into Current Treatment Paradigms

Supported by an educational grant from PDL BioPharma

Estimated Running Time: 1.5 hours

Credit Available: March 2008- March 2009

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Assess clinical trial evidence supporting the role of intravenous antihypertensive agents in the contemporary management of hypertensive crisis
• Formulate strategies for the treatment of acute hypertension in subarachnoid, intracerebral and ischemic stroke, as recommended in current evidenced-based guidelines
• Review controversies related to perioperative blood pressure control in patients undergoing cardiac surgery
• Analyze case studies in hypertensive crisis management

Target Audience
This continuing medical education offering is intended to meet the needs of any healthcare provider involved in the care of critically ill patients, including advance practice nurses, critical care nurses, intensivists, critical care fellows, anesthesiologists, internists, surgeons, cardiologists, pulmonologists, emergency medicine practitioners, neurologists, and respiratory therapists.

Obtaining Credit
Obtaining Credit
Click here to complete the evaluation and credit verification.

Upon receipt, your certificate will be sent to you within 30 days.
If you have any questions, please contact the Continuing Education Department at 847-827-6869 or at education@sccm.org

Physicians/Physician Assistants

SCCM designates this educational activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim credit commensurate with the extent of their participation in the activity.

Nurses
SCCM is approved by the California Board of Registered Nursing, Provider No. 8181, and the American Association of Critical-care Nurses (#00013930) and approves this activity for 1.5 contact hours.

Pharmacists
SCCM is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This activity will provide 1.5 continuing education hours. (236-000-08-151--H01-P)

Faculty Disclosure Statement
Faculty reported the following disclosures for this activity:

William M. Coplin, MD, FCCM
Wayne State University
Detroit Receiving Hospital
Detroit, Michigan, USA
Consultant, Research Grant Recipient, Speakers Bureau: PDL BioPharma, Integra Neurosciences, Medivance, Inc., Astellas
Pharma US

John M. Luber, MD
Franciscan Health System Research
Center Board
Tacoma, Washington, USA
Consultant, Speakers Bureau, Grant Recipient: PDL BioPharma, Scios, Johnson & Johnson

Gene Y. Sung, MD
University of Southern California
Los Angeles, California, USA
Consultant: PDL BioPharma, TheMedicines Company; Grant Recipient, Speakers Bureau: PDL BioPharma